FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2473327384> ?p ?o ?g. }

• W2473327384 endingPage "1045" @default.
• W2473327384 startingPage "1045" @default.
• W2473327384 abstract "Abstract Mutations in genes encoding isocitrate dehydrogenase 1/2 (IDH 1/2) enzymes result in increased 2-hydroxyguterate (2-HG) levels, which may provide a non-invasive marker of disease in IDH-mutant AML. The purpose of this study was to characterize patients with IDH-mutant AML by assessing presenting features, concurrent mutations, and 2-HG levels. From 7-2011 through 6-2014, we identified 170 consecutive patients with newly diagnosed AML and measured 2-HG by liquid chromatography-tandem mass spectrometry in serum, urine, marrow aspirate, and marrow pellet samples. All patients had IDH1 R132, IDH2 R140 and R172 testing; 169/170 had hotspot mutational profiling for AKT1, APC, BRAF, CTNNB1, EGFR, ERBB2, KIT, KRAS, MAP2K1,NOTCH1, NRAS, PIK3CA, P53, and PTEN. We assessed FLT3 (168/170), NPM1 (168/170), CEBPA (100/170) mutational status as routine clinical care; 2 patients had BCR/ABL alterations, and 6 were JAK2 positive (of 36 tested). IDH1/2-mutant were compared to wildtype (WT) patients using a Wilcoxon rank sum test, Fisher's exact test, or Kruskal Wallis test, as appropriate. The group was 54% male; 83% white, 2.4% black, 2.4% Asian, and 6.5% Hispanic. 12 patients had APL. IDH mutations included IDH1 R132C (n=10), IDH2 R172 (n=7), and IDH2 140Q (n=22). Other mutations included NPM1 (20.8%), FLT3-ITD (17.3%), FLT3-TKD (6.6%), NRAS (18.4%), TP53 (3%), KRAS (6.5%), and KIT (1.2%). CEBPA mutations occurred in 13 of 100 patients. IDH mutations (n=39) more frequently co-occurred with normal cytogenetics and NPM1 mutations, vs IDH-WT, consistent with prior reports (Table 1). No patients with favorable cytogenetics harbored an IDH1/2 mutation. Significantly higher 2-HG levels were detected among those with IDH1/2 mutations compared to IDH WT, in the serum (p<0.0001), urine (p<0.0001), marrow aspirate (p<0.0001) and marrow pellet (p<0.0001). Overall, elevated 2-HG levels were present regardless of type of IDH mutation. Serum and marrow pellet 2-HG levels were elevated (> 1000 ng/mL in serum and > 1000ng/2x10^6 cells in marrow pellet) in 30/38 and 24/29 IDH-mutant patients, respectively, compared to 1/129 and 5/117 IDH WT patients. All but 2 IDH-mutant patients displayed either or both an elevated marrow pellet or serum 2-HG. Patients with IDH2 R172 mutations had lower marrow 2HG levels compared to those with R140Q mutations (Figure 1, p=0.0434). The WBC and blast count was lower among IDH2 R172-mutant compared to R140Q- or IDH1 R132C-mutant patients (p= 0.0134 and p=0.0039, respectively); there was no significant difference in serum 2HG levels. All three canonical IDH1/2 mutations have higher 2HG levels compared to IDH WT. IDH2 R172 mutated AML may present with lower WBC counts and peripheral blast percentage compared to IDH1 R132C and IDH2 R140Q mutant AML. Urine and serum 2HG levels effectively identify patients with mutant IDH1/2, of particular relevance given targeted therapies for these mutations. Table 1. Characteristics of IDH1/2-mutant and WT AML patients. IDH1/2 Mutated IDH1/2 WT p-value Age, y (median, range) 67 (41-86) 65 (20-87) 0.4718 AML History (n, %) De Novo 28 (72%) 82 (63%) 0.6336 Therapy-related 4 (10%) 15 (11%) MDS 2 (5%) 17 (13%) Cytogenetic Risk (n, %) Favorable 0 23 (18%) 0.0006 Intermediate 30 (81%) 71 (55%) Normal 25 (68%) 44 (34%) Poor 7 (19%) 34 (27%) Concurrent Mutations (n, %) NPM1 15 (38%) 20 (16%) 0.0033 FLT3-ITD 3 (8%) 26 (20%) 0.0907 FLT3-TKD 2 (5%) 9 (7%) 1.000 CEBPA Heterozygous Homozygous 3 (14%) 0 8 (10%) 2 (3%) 0.8118 NRAS 9 (23%) 22 (17%) 0.4788 KRAS 0 11 (8%) 0.0700 KIT 1 (3%) 1 (1%) 0.4093 P53 1 (3%) 4 (3%) 1.000 Table 2. WBC and 2-HG levels by IDH mutation (median, range). BQL, below quantitative limit. IDH1 R132C N= 10 IDH2 R172 N=7 IDH2 R140Q N=22 IDH WT N=131 WBC count 10.1 [1.8-333.2] 1.6 [0.7-3.2] 5.9 [0.9-122.8] 6.3 [0.4-315.4] Peripheral blast % 33.0 [0-98] 1.0 [0-9.8] 18.2 [2-91] 15 [0-94] Marrow aspirate 2-HG (ng/mL) 20,900 [1330-93500] (n=7) 4300 [2230-26000] (n=6) 30800 [BQL-311000] (n=19) BQL [BQL-22000] (n=116) Serum 2-HG (ng/mL) 1807 [101-66207] (n=9) 1102 [287-2908] (n=7) 1464 [365.1-11696] (n=22) 86.9 [BQL-1224] (n=128) Urine 2-HG (ng/mL) 33850 [7260-282000] (n=10) 7430 [2460-63700] (n=7) 11300 [2070-177000] (n=20) 3140 [BQL-53200] (n=125) Marrow pellet 2-HG (ng/2*10^6 cells) 13680 [193-172,800] (n=7) 7480 [1056-79600] (n=5) 5560 [564-96400] (n=17) 65 [BQL-4040] (n=116) Figure 1 Figure 1. Disclosures Brunner: NIH T32 CA 71345-18: Research Funding. Attar:Agios: Employment. Yen:Agios: Employment. Yang:Agios Pharmaceuticals: Employment, Stockholder Other. Straley:Agios: Employment. Agresta:Agios Pharmaceuticals: Employment, Stockholder Other. Stone:Agios: Consultancy. Fathi:Millennium: Research Funding; Seattle Genetics: Advisory Board, Advisory Board Other; Agios: Advisory Board, Advisory Board Other." @default.
• W2473327384 created "2016-07-22" @default.
• W2473327384 creator A5003947352 @default.
• W2473327384 creator A5009091754 @default.
• W2473327384 creator A5009387581 @default.
• W2473327384 creator A5010057352 @default.
• W2473327384 creator A5010967094 @default.
• W2473327384 creator A5025351031 @default.
• W2473327384 creator A5030996883 @default.
• W2473327384 creator A5031525963 @default.
• W2473327384 creator A5039846257 @default.
• W2473327384 creator A5045583767 @default.
• W2473327384 creator A5050943295 @default.
• W2473327384 creator A5053897548 @default.
• W2473327384 creator A5056275493 @default.
• W2473327384 creator A5056530572 @default.
• W2473327384 creator A5060473465 @default.
• W2473327384 creator A5063673381 @default.
• W2473327384 creator A5071023119 @default.
• W2473327384 creator A5074239788 @default.
• W2473327384 creator A5083259909 @default.
• W2473327384 creator A5089274301 @default.
• W2473327384 date "2014-12-06" @default.
• W2473327384 modified "2023-09-27" @default.
• W2473327384 title "Diagnostic Features and 2-Hydroxyglutarate (2-HG) Levels Among Acute Myeloid Leukemia (AML) Patients with and without Isocitrate Dehydrogenase (IDH) Mutations" @default.
• W2473327384 doi "https://doi.org/10.1182/blood.v124.21.1045.1045" @default.
• W2473327384 hasPublicationYear "2014" @default.
• W2473327384 type Work @default.
• W2473327384 sameAs 2473327384 @default.
• W2473327384 citedByCount "1" @default.
• W2473327384 countsByYear W24733273842023 @default.
• W2473327384 crossrefType "journal-article" @default.
• W2473327384 hasAuthorship W2473327384A5003947352 @default.
• W2473327384 hasAuthorship W2473327384A5009091754 @default.
• W2473327384 hasAuthorship W2473327384A5009387581 @default.
• W2473327384 hasAuthorship W2473327384A5010057352 @default.
• W2473327384 hasAuthorship W2473327384A5010967094 @default.
• W2473327384 hasAuthorship W2473327384A5025351031 @default.
• W2473327384 hasAuthorship W2473327384A5030996883 @default.
• W2473327384 hasAuthorship W2473327384A5031525963 @default.
• W2473327384 hasAuthorship W2473327384A5039846257 @default.
• W2473327384 hasAuthorship W2473327384A5045583767 @default.
• W2473327384 hasAuthorship W2473327384A5050943295 @default.
• W2473327384 hasAuthorship W2473327384A5053897548 @default.
• W2473327384 hasAuthorship W2473327384A5056275493 @default.
• W2473327384 hasAuthorship W2473327384A5056530572 @default.
• W2473327384 hasAuthorship W2473327384A5060473465 @default.
• W2473327384 hasAuthorship W2473327384A5063673381 @default.
• W2473327384 hasAuthorship W2473327384A5071023119 @default.
• W2473327384 hasAuthorship W2473327384A5074239788 @default.
• W2473327384 hasAuthorship W2473327384A5083259909 @default.
• W2473327384 hasAuthorship W2473327384A5089274301 @default.
• W2473327384 hasConcept C104317684 @default.
• W2473327384 hasConcept C121608353 @default.
• W2473327384 hasConcept C126322002 @default.
• W2473327384 hasConcept C127848430 @default.
• W2473327384 hasConcept C143065580 @default.
• W2473327384 hasConcept C143998085 @default.
• W2473327384 hasConcept C181199279 @default.
• W2473327384 hasConcept C21790070 @default.
• W2473327384 hasConcept C2483381 @default.
• W2473327384 hasConcept C2776059313 @default.
• W2473327384 hasConcept C2777150147 @default.
• W2473327384 hasConcept C2778729363 @default.
• W2473327384 hasConcept C2781187634 @default.
• W2473327384 hasConcept C30481170 @default.
• W2473327384 hasConcept C45091340 @default.
• W2473327384 hasConcept C501734568 @default.
• W2473327384 hasConcept C502942594 @default.
• W2473327384 hasConcept C526805850 @default.
• W2473327384 hasConcept C53226629 @default.
• W2473327384 hasConcept C54355233 @default.
• W2473327384 hasConcept C55493867 @default.
• W2473327384 hasConcept C71924100 @default.
• W2473327384 hasConcept C86803240 @default.
• W2473327384 hasConceptScore W2473327384C104317684 @default.
• W2473327384 hasConceptScore W2473327384C121608353 @default.
• W2473327384 hasConceptScore W2473327384C126322002 @default.
• W2473327384 hasConceptScore W2473327384C127848430 @default.
• W2473327384 hasConceptScore W2473327384C143065580 @default.
• W2473327384 hasConceptScore W2473327384C143998085 @default.
• W2473327384 hasConceptScore W2473327384C181199279 @default.
• W2473327384 hasConceptScore W2473327384C21790070 @default.
• W2473327384 hasConceptScore W2473327384C2483381 @default.
• W2473327384 hasConceptScore W2473327384C2776059313 @default.
• W2473327384 hasConceptScore W2473327384C2777150147 @default.
• W2473327384 hasConceptScore W2473327384C2778729363 @default.
• W2473327384 hasConceptScore W2473327384C2781187634 @default.
• W2473327384 hasConceptScore W2473327384C30481170 @default.
• W2473327384 hasConceptScore W2473327384C45091340 @default.
• W2473327384 hasConceptScore W2473327384C501734568 @default.
• W2473327384 hasConceptScore W2473327384C502942594 @default.
• W2473327384 hasConceptScore W2473327384C526805850 @default.
• W2473327384 hasConceptScore W2473327384C53226629 @default.
• W2473327384 hasConceptScore W2473327384C54355233 @default.
• W2473327384 hasConceptScore W2473327384C55493867 @default.
• W2473327384 hasConceptScore W2473327384C71924100 @default.
• W2473327384 hasConceptScore W2473327384C86803240 @default.

• next